Tag: In the News

Data highlight the importance of utilizing genomic and proteomic testing for treatment guidance BOULDER, CO, September 15,2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association…

BOULDER, Colo.–(BUSINESS WIRE)–August 24, 2021— Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on…

Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research BOULDER, Colo.–(BUSINESS WIRE)–Jun. 17, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present…

Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo. — June 15, 2021— Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.).…

Biodesix intends to make its databank and linked data accessible to research and biopharma partners Boulder, Colorado & San Francisco, California – June 2, 2021 – Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help…

Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy San Carlos, CA and Boulder, CO, May 26, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,…

BOULDER, Colo. — Apr. 26, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021. William Blair 41st Annual Growth Stock ConferenceDate: Wednesday, June 2, 2021Time: 2:00 PM CT The presentation will…

  First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests – SARS-CoV-2 Neutralization Antibody Detection Test and Next Generation Sequencing Test   BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung…

BOULDER, Colo.–(BUSINESS WIRE)–Apr. 26, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results…

Blood-based NGS Test is Shown in Recent Publication to Provide Critical Data in 72 Hours; Launch Planned for First Half of 2022 BOULDER, CO, April 28, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing…